Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. More Details
No risks detected for AGFB from our risk checks.
Excellent balance sheet and fair value.
Share Price & News
How has Agfa-Gevaert's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGFB has not had significant price volatility in the past 3 months.
7 Day Return
BE Healthcare Services
1 Year Return
BE Healthcare Services
Return vs Industry: AGFB underperformed the Belgian Healthcare Services industry which returned 15% over the past year.
Return vs Market: AGFB exceeded the Belgian Market which returned -25.2% over the past year.
Price Volatility Vs. Market
How volatile is Agfa-Gevaert's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAgfa-Gevaert (EBR:AGFB) Shareholders Booked A 66% Gain In The Last Five Years
3 months ago | Simply Wall StHere's Why Agfa-Gevaert (EBR:AGFB) Has A Meaningful Debt Burden
4 months ago | Simply Wall StInvestors Who Bought Agfa-Gevaert (EBR:AGFB) Shares Five Years Ago Are Now Up 61%
Is Agfa-Gevaert undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AGFB (€3.5) is trading below our estimate of fair value (€28.26)
Significantly Below Fair Value: AGFB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AGFB is unprofitable, so we can't compare its PE Ratio to the XE Healthcare Services industry average.
PE vs Market: AGFB is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGFB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGFB is good value based on its PB Ratio (0.8x) compared to the XE Healthcare Services industry average (4.8x).
How is Agfa-Gevaert forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGFB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGFB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGFB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGFB's revenue is expected to decline over the next 3 years (-2.6% per year).
High Growth Revenue: AGFB's revenue is forecast to decline over the next 3 years (-2.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGFB's Return on Equity is forecast to be high in 3 years time
How has Agfa-Gevaert performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGFB is currently unprofitable.
Growing Profit Margin: AGFB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGFB is unprofitable, and losses have increased over the past 5 years at a rate of 63.1% per year.
Accelerating Growth: Unable to compare AGFB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGFB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-11.5%).
Return on Equity
High ROE: AGFB has a negative Return on Equity (-12.79%), as it is currently unprofitable.
How is Agfa-Gevaert's financial position?
Financial Position Analysis
Short Term Liabilities: AGFB's short term assets (€1.8B) exceed its short term liabilities (€629.0M).
Long Term Liabilities: AGFB's short term assets (€1.8B) exceed its long term liabilities (€1.1B).
Debt to Equity History and Analysis
Debt Level: AGFB's debt to equity ratio (1.8%) is considered satisfactory.
Reducing Debt: AGFB's debt to equity ratio has reduced from 127.7% to 1.8% over the past 5 years.
Debt Coverage: AGFB's debt is well covered by operating cash flow (821.4%).
Interest Coverage: AGFB is unprofitable, therefore interest payments are not well covered by earnings.
What is Agfa-Gevaert current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGFB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGFB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGFB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGFB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGFB's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Pascal Juery (55 yo)
Mr. Pascal Juéry serves as Chief Executive Officer at Agfa-Gevaert NV since February 1, 2020 and also serves as its President since 2020. Mr. Juéry serves as a Director of Agfa-Gevaert NV since 2020 and al ...
|President||0.58yr||no data||no data|
|Chief Financial Officer||2.33yrs||no data||no data|
|Compliance Officer & Company Secretary||no data||no data||no data|
|Director of Corporate Communications||12yrs||no data||no data|
|Executive Vice President||no data||no data||no data|
|President of Offset Solutions||12.33yrs||no data||no data|
|President of Agfa Healthcare||no data||no data||no data|
Experienced Management: AGFB's management team is seasoned and experienced (7.2 years average tenure).
|President||0.58yr||no data||no data|
|Independent Director||5.33yrs||€70.00k||no data|
|Independent Director||1.33yrs||€62.50k||no data|
|Non-Executive Director||1.83yrs||€180.00k||no data|
|Independent Director||2.33yrs||€77.50k||no data|
|Independent Chairman of the Board||0.67yr||€60.00k||no data|
Experienced Board: AGFB's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Agfa-Gevaert NV's company bio, employee growth, exchange listings and data sources
- Name: Agfa-Gevaert NV
- Ticker: AGFB
- Exchange: ENXTBR
- Founded: 1867
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: €586.290m
- Shares outstanding: 167.75m
- Website: https://www.agfa.com
Number of Employees
- Agfa-Gevaert NV
- Septestraat 27
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AFGV.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 1999|
|AGFB||ENXTBR (Euronext Brussels)||Yes||Ordinary Shares||BE||EUR||Jun 1999|
|AGE||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 1999|
|0MFU||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jun 1999|
|AGFBB||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jun 1999|
|AGFB||SWX (SIX Swiss Exchange)||Yes||Ordinary Shares||CH||CHF||Jun 1999|
|AFGV.Y||OTCPK (Pink Sheets LLC)||ADR||US||USD||Oct 2008|
Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The company’s Offset Solutions segment provides commercial, newspaper, and packag ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 04:43|
|End of Day Share Price||2020/09/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.